Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Do statins play a role in renoprotection?

Kasahara M, Nakagawa T, Yokoi H, Kuwabara T, Yasuno S, Mori K, Mukoyama M, Ueshima K.

Clin Exp Nephrol. 2014 Apr;18(2):282-5. doi: 10.1007/s10157-013-0928-z. Epub 2014 Jan 10. Review.

PMID:
24408222
2.

Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: rationale and design of the ASsessment of clinical Usefulness in CKD patients with Atorvastatin (ASUCA) trial.

Ueshima K, Kasahara M, Koya D, Babazono T, Sato T, Imamoto M, Yasuno S, Fujimoto A, Tanaka S, Kimura G, Nakao K.

Clin Exp Nephrol. 2013 Apr;17(2):211-7. doi: 10.1007/s10157-012-0676-5. Epub 2012 Sep 6.

PMID:
22948416
3.

Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial.

Kimura G, Kasahara M, Ueshima K, Tanaka S, Yasuno S, Fujimoto A, Sato T, Imamoto M, Kosugi S, Nakao K.

Clin Exp Nephrol. 2017 Jun;21(3):417-424. doi: 10.1007/s10157-016-1304-6. Epub 2016 Jul 8.

4.

[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].

Karie S, Launay-Vacher V, Deray G, Isnard-Bagnis C.

Presse Med. 2006 Feb;35(2 Pt 1):219-29. Review. French.

PMID:
16493350
5.

Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?

Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP.

Expert Opin Pharmacother. 2015;16(10):1449-61. doi: 10.1517/14656566.2015.1053464. Epub 2015 Jun 3. Review.

PMID:
26037614
6.

Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial.

Amarenco P, Callahan A 3rd, Campese VM, Goldstein LB, Hennerici MG, Messig M, Sillesen H, Welch KM, Wilson DJ, Zivin JA.

Stroke. 2014 Oct;45(10):2974-82. doi: 10.1161/STROKEAHA.114.005832. Epub 2014 Aug 21.

7.

Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs.

Campese VM.

Clin Exp Nephrol. 2014 Apr;18(2):291-5. doi: 10.1007/s10157-014-0934-9. Epub 2014 Feb 18. Review.

PMID:
24535025
8.

[USE OF STATINS IN PATIENTS WITH CHRONIC KIDNEY DISEASE TO PREVENT CARDIOVASCULAR DISEASE].

Zavidić T, Lodeta B, Lovrinić Đ.

Acta Med Croatica. 2016 Dec;70(4-5):301-7. Review. Croatian.

PMID:
29087163
9.

Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).

Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Charlton-Menys V, DeMicco DA, Fuller JH; CARDS Investigators.

Am J Kidney Dis. 2009 Nov;54(5):810-9. doi: 10.1053/j.ajkd.2009.03.022. Epub 2009 Jun 21.

PMID:
19540640
10.

HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.

Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Hegbrant J, Strippoli GF.

Cochrane Database Syst Rev. 2014 May 31;(5):CD007784. doi: 10.1002/14651858.CD007784.pub2. Review.

PMID:
24880031
11.

Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis.

Hou W, Lv J, Perkovic V, Yang L, Zhao N, Jardine MJ, Cass A, Zhang H, Wang H.

Eur Heart J. 2013 Jun;34(24):1807-17. doi: 10.1093/eurheartj/eht065. Epub 2013 Mar 6. Review.

PMID:
23470492
12.

Epidemiology of dyslipidemia in chronic kidney disease.

Iseki K.

Clin Exp Nephrol. 2014 Apr;18(2):185-8. doi: 10.1007/s10157-013-0891-8. Epub 2014 Jan 11. Review.

PMID:
24408220
13.

3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the progression of renal dysfunction in Japanese hypertensive patients.

Kuwabara M, Kubo T, Bando K, Hirakawa Y, Kitaoka H, Nishinaga M, Doi YL.

Geriatr Gerontol Int. 2010 Jul;10(3):219-24. doi: 10.1111/j.1447-0594.2010.00584.x. Epub 2010 Feb 4.

PMID:
20141537
14.

Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy.

Athyros VG, Tziomalos K, Karagiannis A.

Expert Rev Cardiovasc Ther. 2015;13(9):1059-66. doi: 10.1586/14779072.2015.1072047. Epub 2015 Jul 23. Review.

PMID:
26206619
15.

[Statins and kidney disease].

Bigazzi R, Grimaldi D, Bianchi S.

G Ital Nefrol. 2012 Mar-Apr;29(2):160-73. Review. Italian.

PMID:
22538946
16.

Improvement in Renal Function and Reduction in Serum Uric Acid with Intensive Statin Therapy in Older Patients: A Post Hoc Analysis of the SAGE Trial.

Deedwania PC, Stone PH, Fayyad RS, Laskey RE, Wilson DJ.

Drugs Aging. 2015 Dec;32(12):1055-65. doi: 10.1007/s40266-015-0328-z.

17.

Statins and lipid-lowering strategies in cardiorenal patients.

Bianchi S, Grimaldi D, Bigazzi R.

Contrib Nephrol. 2011;171:143-50. doi: 10.1159/000327139. Epub 2011 May 23. Review.

PMID:
21625103
18.

Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.

Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK; TNT (Treating to New Targets) Investigators.

J Am Coll Cardiol. 2008 Apr 15;51(15):1448-54. doi: 10.1016/j.jacc.2007.11.072.

19.

Statins in chronic kidney disease: cardiovascular risk and kidney function.

Deedwania PC.

Postgrad Med. 2014 Jan;126(1):29-36. doi: 10.3810/pgm.2014.01.2722. Review.

PMID:
24393749
20.

Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study.

Athyros VG, Karagiannis A, Ganotakis ES, Paletas K, Nicolaou V, Bacharoudis G, Tziomalos K, Alexandrides T, Liberopoulos EN, Mikhailidis DP; Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabeTes (ATTEMPT) Collaborative Group.

Curr Med Res Opin. 2011 Aug;27(8):1659-68. doi: 10.1185/03007995.2011.595782. Epub 2011 Jun 30.

PMID:
21714711

Supplemental Content

Support Center